Ulcerative Colitis: key endpoint results by drug
The key endpoints of Ulcerative Colitis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Ulcerative Colitis page.
Clinical remission (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 10% | 11.5% | −1.5 | 160 mg/80 mg · wk 8 · n 90 | NCT00853099 Phase 3, primary |
| afimkibart | 23.9% | 11.6% | +12.3 | 450 mg · wk 14 · n 88 | NCT04090411 Phase 2, primary |
| duvakitug | 47.8% | 20.5% | +27.3 | 900 mg · wk 14 · n 46 | NCT05499130 Phase 2b, primary |
| etrasimod | 27% | 7.4% | +19.6 | 2 mg · wk 12 · n 274 | NCT03945188 Phase 3, primary |
| golimumab | 17.9% | 6.4% | +11.5 | 400 mg -> 200 mg · wk 6 · n 257 | NCT00487539 Phase 2/3, secondary |
| guselkumab | 22.6% | 7.9% | +14.7 | 200 mg IV · wk 12 · n 421 | NCT04033445 Phase 3, primary |
| mirikizumab | 24.2% | 13.3% | +10.9 | 300 mg IV Q4W · wk 12 · n 868 | NCT03518086 Phase 3, primary |
| obefazimod | 17.5% | 12.5% | +5 | 50 mg · wk 8 · n 63 | NCT03760003 Phase 2, secondary |
| ozanimod | 18.4% | 6% | +12.4 | wk 10 · n 429 | NCT02435992 Phase 3, primary |
| risankizumab | 20.3% | 6.2% | +14.1 | 1200 mg IV · wk 12 · n 650 | NCT03398148 Phase 2/3, primary |
| tofacitinib | 16.6% | 3.6% | +13 | 10 mg BID · wk 8 · n 429 | NCT01458951 Phase 3, primary |
| tulisokibart | 26.5% | 1.5% | +25 | wk 12 · n 68 | NCT04996797 Phase 2, primary |
| upadacitinib | 26.1% | 4.8% | +21.3 | 45 mg · wk 8 · n 319 | NCT02819635 Phase 2/3, primary |
| ustekinumab | 15.6% | 5.3% | +10.3 | 130 mg IV · wk 8 · n 320 | NCT02407236 Phase 3, primary |
| vedolizumab | 18.3% | 12.2% | +6.1 | 300 mg · wk 10 · n 164 | NCT02039505 Phase 3, secondary |
Drugs checked with no result here: 8 trial running, 65 not reported, 4 not posted.
Clinical remission (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 20% | 7.3% | +12.7 | 160 mg/80 mg · wk 52 · n 90 | NCT00853099 Phase 3, primary |
| etrasimod | 32.1% | 6.7% | +25.4 | 2 mg · wk 52 · n 274 | NCT03945188 Phase 3, primary |
| guselkumab | 50% | 18.9% | +31.1 | 200 mg SC q4w · wk 44 · n 190 | NCT04033445 Phase 3, primary |
| mirikizumab | 49.9% | 25.1% | +24.8 | 200 mg SC · wk 40 · n 365 | NCT03524092 Phase 3, primary |
| ozanimod | 37% | 18.5% | +18.5 | wk 52 · n 230 | NCT02435992 Phase 3, primary |
| tofacitinib | 40.6% | 11.1% | +29.5 | 10 mg BID · wk 52 · n 197 | NCT01458574 Phase 3, primary |
| upadacitinib | 51.7% | 12.1% | +39.6 | 30 mg · wk 52 · n 154 | NCT02819635 Phase 2/3, primary |
| ustekinumab | 43.8% | 24% | +19.8 | 90 mg SC every 8 weeks (q8w) · wk 44 · n 176 | NCT02407236 Phase 3, primary |
| vedolizumab | 46.2% | 14.3% | +31.9 | 108 mg SC · wk 52 · n 106 | NCT02611830 Phase 3, primary |
Drugs checked with no result here: 14 trial running, 65 not reported, 4 not posted.
Clinical response (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 50% | 35.4% | +14.6 | 160 mg/80 mg · wk 8 · n 90 | NCT00853099 Phase 3, secondary |
| duvakitug | 69.6% | 52.3% | +17.3 | 900 mg · wk 14 · n 46 | NCT05499130 Phase 2b, secondary |
| etrasimod | 62.4% | 34.1% | +28.3 | 2 mg · wk 12 · n 274 | NCT03945188 Phase 3, secondary |
| golimumab | 54.9% | 30.3% | +24.6 | 400 mg -> 200 mg · wk 6 · n 257 | NCT00487539 Phase 2/3, primary |
| guselkumab | 61.4% | 27.6% | +33.8 | 200 mg IV · wk 12 · n 101 | NCT04033445 Phase 3, primary |
| mirikizumab | 63.5% | 42.2% | +21.3 | 300 mg IV Q4W · wk 12 · n 868 | NCT03518086 Phase 3, secondary |
| obefazimod | 58.7% | 34.4% | +24.3 | 50 mg · wk 8 · n 63 | NCT03760003 Phase 2, secondary |
| ozanimod | 47.8% | 25.9% | +21.9 | wk 10 · n 429 | NCT02435992 Phase 3, secondary |
| risankizumab | 64.3% | 35.7% | +28.6 | 1200 mg IV · wk 12 · n 650 | NCT03398148 Phase 2/3, secondary |
| spesolimab | 0.3% | 0.2% | ±0 | 1200 mg q4w · wk 12 · n 28 | NCT03482635 Phase 2/3, secondary |
| tofacitinib | 55% | 28.6% | +26.4 | 10 mg BID · wk 8 · n 429 | NCT01458951 Phase 3, secondary |
| tulisokibart | 66.2% | 22.4% | +43.8 | wk 12 · n 68 | NCT04996797 Phase 2, secondary |
| upadacitinib | 72.6% | 27.3% | +45.3 | 45 mg · wk 8 · n 319 | NCT02819635 Phase 2/3, secondary |
| ustekinumab | 51.3% | 31.3% | +20 | 130 mg IV · wk 8 · n 320 | NCT02407236 Phase 3, secondary |
| vedolizumab | 39.6% | 32.9% | +6.7 | 300 mg · wk 10 · n 164 | NCT02039505 Phase 3, primary |
Drugs checked with no result here: 9 trial running, 64 not reported, 4 not posted.
Endoscopic improvement (induction)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 44.4% | 30.2% | +14.2 | 160 mg/80 mg · wk 8 · n 90 | NCT00853099 Phase 3, secondary |
| afimkibart | 40.9% | 18.6% | +22.3 | 450 mg · n 88 | NCT04090411 Phase 2, secondary |
| etrasimod | 35% | 14.1% | +20.9 | 2 mg · wk 12 · n 274 | NCT03945188 Phase 3, secondary |
| mirikizumab | 13.1% | 6.3% | +6.8 | 600 mg IV Q4W · wk 12 · n 61 | NCT02589665 Phase 2, secondary |
| ozanimod | 27.3% | 11.6% | +15.7 | wk 10 · n 429 | NCT02435992 Phase 3, secondary |
| risankizumab | 36.5% | 12.1% | +24.4 | 1200 mg IV · wk 12 · n 650 | NCT03398148 Phase 2/3, secondary |
| tofacitinib | 28.4% | 11.6% | +16.8 | 10 mg BID · wk 8 · n 429 | NCT01458951 Phase 3, secondary |
| tulisokibart | 36.8% | 6% | +30.8 | wk 12 · n 68 | NCT04996797 Phase 2, secondary |
| upadacitinib | 36.3% | 7.4% | +28.9 | 45 mg · wk 8 · n 319 | NCT02819635 Phase 2/3, secondary |
| vedolizumab | 36.6% | 30.5% | +6.1 | 300 mg · wk 10 · n 164 | NCT02039505 Phase 3, secondary |
Drugs checked with no result here: 13 trial running, 65 not reported, 4 not posted.
Corticosteroid-free remission (maintenance)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 13.3% | 5.7% | +7.6 | 160/80/40 · wk 52 · n 150 | NCT00408629 Phase 3, secondary |
| etrasimod | 32.1% | 6.7% | +25.4 | 2 mg · wk 52 · n 274 | NCT03945188 Phase 3, secondary |
| golimumab | 23.2% | 18.4% | +4.8 | 100 mg · wk 54 · n 82 | NCT00488631 Phase 3, secondary |
| ozanimod | 31.7% | 16.7% | +15 | wk 52 · n 230 | NCT02435992 Phase 3, secondary |
| ustekinumab | 42% | 23.4% | +18.6 | 90 mg SC every 8 weeks (q8w) · wk 44 · n 176 | NCT02407236 Phase 3, secondary |
| vedolizumab | 28.9% | 8.3% | +20.6 | 108 mg SC · wk 52 · n 45 | NCT02611830 Phase 3, secondary |
Drugs checked with no result here: 16 trial running, 5 not posted, 65 not reported.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 92 approved or late-stage drugs with a featured trial in Ulcerative Colitis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.